Abstract Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are associated with an increased response to gefitinib in patients with non^small cell lung cancer. We have examined the impact of gefitinib on progression-free survival and overall survival in patients with EGFR mutation^positive non^small cell lung cancer. Experimental Design: We searched for all clinical trials that prospectively evaluated the efficacy of gefitinib for advanced non^small cell lung cancer with EGFR mutations in Japan. We did a combined analysis based on individual patient data from the identified trials. Results: Seven eligible trials were identified for a total of 148 non^small cell lung cancer patients with EGFR mutations. The overall response rate to gefitinib was 76.4% [95% confidence interval (95% CI), 69.5-83.2]. The median progression-free survival and overall survival were 9.7 months (95% CI, 8.2-11.1) and 24.3 months (95% CI, 19.8-28.2), respectively. Good performance status and chemotherapy-naI« ve status were significantly associated with a longer progression-free survival or overall survival. Of the 148 patients, 87 received gefitinib as a first-line therapy, whereas 61received systemic chemotherapy before gefitinib treatment. The median progression-free survival after the start of first-line therapy was significantly longer in the gefitinib-first group than in the chemotherapy-first group (10.7 versus 6.0 months; P < 0.001), whereas no significant difference in median overall survival was apparent between the two groups (27.7 versus 25.7 months; P = 0.782). Conclusions: Gefitinib monotherapy confers substantial clinical benefit in terms of progressionfree survival and overall survival in non^small cell lung cancer patients with EGFR mutations. Randomized trials comparing chemotherapy with gefitinib as a first-line treatment are warranted in such patients.
Non-small cell lung cancer is the leading cause of death related to cancer worldwide (1) . Cytotoxic chemotherapy remains the mainstay of treatment for patients with metastatic non -small cell lung cancer on the basis of the associated moderate improvement in survival and quality of life (2 -4) . The poor outlook even for patients with advanced non -small cell lung cancer who receive such chemotherapy has prompted a search for new therapeutic approaches.
The epidermal growth factor receptor (EGFR) is frequently overexpressed in non -small cell lung cancer and has been implicated in the pathogenesis of this disease (5, 6) . Given the biological importance of EGFR signaling in non -small cell lung cancer, EGFR-specific tyrosine kinase inhibitors, including gefitinib and erlotinib, have been extensively studied in patients with this condition (7 -10) . We and others have shown that a clinical response to these agents is more common in women than in men, in Japanese than in individuals from Europe or the United States, in patients with adenocarcinoma than in those with other histologic subtypes of cancer, and in individuals who have never smoked than in those with a history of smoking (11) . Somatic activating mutations in the EGFR gene (EGFR) have also been identified as a major determinant of the clinical response to treatment with gefitinib or erlotinib (12 -14) . EGFR mutations are present more frequently in neversmokers, females, individuals with adenocarcinoma, and patients of East Asian ethnicity (15 -18) , the same groups identified clinically as most likely to respond to treatment with EGFR tyrosine kinase inhibitors.
Several prospective clinical trials of gefitinib or erlotinib for treatment of non -small cell lung cancer patients with EGFR mutations have been done to date (18 -26) . These trials have shown radiographic response rates ranging from 55% to 82% and a median progression-free survival of 8.9 to 13.3 months. These values are three to four times those historically observed with platinum-based chemotherapy as a first-line treatment for advanced non -small cell lung cancer. As the data accumulate, it seems clear that non -small cell lung cancer patients with EGFR mutations exhibit a distinct clinical response to treatment with EGFR tyrosine kinase inhibitors. An improvement in overall survival conferred by treatment with these drugs is also expected in patients harboring EGFR mutations. However, it was not possible to evaluate overall survival in most of the clinical trials at the time of publication because the number of patients was not sufficiently large and the follow-up period was not long enough to obtain precise estimates of survival outcome.
We have now done a combined analysis based on individual patient data from prospective phase II trials of gefitinib monotherapy in non -small cell lung cancer patients with EGFR mutations. The present study was designated I-CAMP for Iressa Combined Analysis of Mutation Positives. Our main aim was to update the effects of gefitinib treatment on survival end points in the selected population of patients. We further explored the efficacy of gefitinib administration as a first-line treatment for EGFR mutation -positive patients in comparison with conventional cytotoxic chemotherapy.
Materials and Methods
Study selection. We searched for all clinical trials conducted in Japan that prospectively evaluated the efficacy of gefitinib monotherapy for advanced non -small cell lung cancer associated with EGFR mutations. The search was done with PubMed and the Proceedings of the American Society of Clinical Oncology covering the period from 2004 to 2008. Seven phase II trials were identified, all of which were published (19 -25) . All identified trials, including genomic analysis of stored or collected tumor tissue, were approved by institutional review boards, and EGFR mutations were determined either by direct sequencing, by common fragment analysis of PCRmediated amplification products for exon 19 deletions and cycleave real-time PCR for the L858R point mutation (26) , or by the peptide nucleic acid -locked nucleic acid PCR clamp method (27) . All trials had the same treatment schedule, consisting of the oral administration of 250 mg of gefitinib once a day. In some trials, gefitinib was the first-line treatment, whereas in others, it was administered after cytotoxic chemotherapy. The primary end point of these trials was tumor response rate, which was assessed according to the Response Evaluation Criteria in Solid Tumors (28) .
Collection of individual patient data. The study was done in accordance with the Declaration of Helsinki (1964, amended in 2000) and the Ethical Guidelines for Epidemiologic Study (Ministry of Health, Labor, and Welfare of Japan, 2002). The primary objective of the study was to determine the impact of gefitinib treatment for EGFR mutation -positive non -small cell lung cancer on overall survival on the basis of examination of individual data from 148 patients enrolled in the seven selected trials. Secondary objectives included evaluation of response, progression-free survival, and safety for gefitinib, and to compare progression-free survival and overall survival for first-line gefitinib treatment with those for first-line chemotherapy administered before gefitinib. The medical records of patients in the seven identified studies were reviewed for patient characteristics, drug side effects, tumor response, progression-free survival, and overall survival. Patient characteristics noted included sex, age, Eastern Cooperative Oncology Group (ECOG) performance status, tumor histology, tumor-node-metastasis staging, postoperative disease recurrence, smoking history, previous chemotherapy, and type of EGFR mutation. All adverse events with a grade of z3 according 
Translational Relevance
Somatic mutations of the epidermal growth factor receptor (EGFR) are associated with response of advanced non^small cell lung cancer to EGFR-specific tyrosine kinase inhibitors such as gefitinib and erlotinib. Prospective phase II trials of gefitinib monotherapy for advanced nonŝ mall cell lung cancer with EGFR mutations have found higher response rates than those observed with conventional chemotherapy. However, overall survival data have not been available because of the short follow-up period in these trials. We have now analyzed updated individual patient data from sevenJapanese prospective phase II trials of gefitinib monotherapy, including a total of 148 EGFR mutation^positive individuals.We found that gefitinib confers a highly favorable progression-free survival (9.7 months) and overall survival (24.3 months) in such patients. Furthermore, an exploratory comparison between gefitinib and systemic chemotherapy in the first-line setting suggests that gefitinib monotherapy is an effective first-line treatment for EGFR mutation^positive non^small cell lung cancer. These results have potentially important implications for the treatment of non^small cell lung cancer associated with EGFR mutations.
to the National Cancer Institute -Common Toxicity Criteria (version 3.0) were recorded, as was interstitial lung disease of any grade. The clinical data for first-line chemotherapy administered before gefitinib were obtained retrospectively. In accordance with Response Evaluation Criteria in Solid Tumors, objective tumor responses were classified as complete response, partial response, stable disease, or progressive disease. For analysis of progression-free survival and overall survival, the day of initiation of gefitinib treatment, the day tumor progression was detected, and the last day that survival was evaluated or the day of death were noted. In addition, clinically important prognostic factors were examined.
Statistical analysis. Overall survival was defined as the time from the initiation of gefitinib monotherapy until death from any cause. Progression-free survival was defined as the time from the initiation of gefitinib monotherapy to the first observation of disease progression or death from any cause. Progression-free survival and overall survival were analyzed by the Kaplan-Meier method and were compared between groups by the log-rank test. Prognostic factors for progression-free survival and overall survival were examined by the Cox regression model, with adjustment for covariates, including sex (female versus male), smoking history (never-smoker versus smoker), tumornode-metastasis stage (IIIB versus advanced), ECOG performance status (0 or 1 versus 2 to 4), the number of previous chemotherapy regimens (0 versus 1 to 3), and type of EGFR mutation (L858R versus exon 19 deletion). Differences in characteristics between patient groups according to first-line therapy were evaluated by the m 2 test. A P of <0.05 was considered statistically significant.
Results
Patient characteristics. The characteristics of the 148 EGFR mutation -positive non -small cell lung cancer patients are summarized in Table 1 . The median age was 65 years, with a range of 33 to 89 years. A total of 102 patients (69%) were women, and 105 patients (71%) were never-smokers. The most common tumor histology was adenocarcinoma, which was present in 143 patients (97%). Whereas 88 patients had a single EGFR mutation consisting of an exon 19 deletion, 56 patients had a single mutation consisting of L858R in exon 21 and the remaining 4 patients had double or triple mutations involving an exon 19 deletion or L858R.
Drug safety and toxicity. Most treatment-related toxicity was mild, being of National Cancer Institute -Common Toxicity Criteria grade 1 or 2. Adverse events of grade 3 or 4 included skin rash (2.7%), diarrhea (1.4%), interstitial lung disease (2.7%), and abnormal liver function, including elevated aspartate aminotransferase or alanine aminotransferase (8.1%). There were no treatment-related deaths.
Response and survival. Eleven patients (7%) showed a complete response and 102 individuals (69%) achieved a partial response to gefitinib monotherapy, yielding an objective response rate of 76.4% [95% confidence interval (95% CI), 69.5-83.2] and substantiating the individual observations of At the time of analysis, the median follow-up time was 20.7 months. The median progression-free survival was 9.7 months (95% CI, 8.2-11.1), and the 1-year progression-free survival rate was 37.7% (95% CI, 29.7-45.7; Fig. 1A ). The median overall survival was 24.3 months (95% CI, 19.8-28.2), and the 1-year overall survival rate was 76.7% (95% CI, 69.8-83.6; Fig. 1B ). Cox regression analysis revealed that an ECOG performance status of 0 or 1 and chemotherapynaBve status were significantly associated with a longer progression-free survival or overall survival (Table 2) .
Comparison between gefitinib and cytotoxic chemotherapy as first-line treatment. Of the 148 EGFR mutation -positive non -small cell lung cancer patients, 87 received gefitinib as first-line therapy whereas 61 received systemic chemotherapy as first-line treatment, followed by gefitinib. Clinical information was assembled retrospectively for the patients who received first-line chemotherapy before gefitinib treatment. The clinicopathologic data for these two groups of patients are shown in Table 3 . The proportion of patients with a poor ECOG performance status (z2) was higher in the first-line gefitinib group (20%) than in the first-line chemotherapy group (7%; P = 0.026). The response rate was significantly higher for the first-line gefitinib group than for the first-line chemotherapy group (79.3% versus 24.6%; P < 0.001; Table 4 ). Kaplan-Meier analysis of progression-free survival and overall survival after the start of first-line antitumor therapy is shown in Fig. 2 . The log-rank test revealed that progression-free survival was significantly longer in the first-line gefitinib group than in the first-line chemotherapy group (median of 10.7 versus 6.0 months; Fig. 2A ), whereas there was no significant difference in overall survival between the two groups of patients (median of 27.7 versus 25.7 months, respectively; Fig. 2B ). Cox regression analysis yielded similar results for progression-free survival and overall survival.
Discussion
EGFR mutations were first associated with non -small cell lung cancer in 2004, and several prospective phase II trials of gefitinib or erlotinib for treatment of non -small cell lung cancer patients with activating EGFR mutations have subsequently been reported (12 -14) . The primary end point of these prospective trials was objective response rate, with the result that overall survival data were not complete because of the short follow-up periods. We have now analyzed the updated individual data for 148 EGFR mutation -positive non -small cell lung cancer patients enrolled in seven prospective phase II trials of gefitinib monotherapy in Japan. The median progression-free survival and overall survival were 9.7 months (95% CI, 8.2-11.1) and 24.3 months (95% CI, 19.8-28.2), respectively. These findings reveal a markedly improved outcome with gefitinib therapy compared with that typically observed with systemic chemotherapy in patients with advanced nonsmall cell lung cancer.
The number of EGFR mutation -positive patients examined in the present study is sufficient to allow comparison of progression-free survival and overall survival among nonsmall cell lung cancer patients with different clinicopathologic characteristics. Previous studies have shown that EGFR mutations are more frequent in females, individuals with no history of smoking, and patients with adenocarcinoma, and that these characteristics are also associated with a higher response rate and longer survival after gefitinib treatment (16 -18) . We have now found that sex and smoking status were not significantly associated with progression-free survival or overall survival among patients with EGFR mutations, indicating that such mutations, regardless of sex and smoking status, are the most appropriate determinant for gefitinib treatment. These findings suggest that analysis of EGFR mutation status is warranted for NOTE: Ps for differences between the two groups of patients were determined by the m 2 test, with that for ECOG performance status being determined for comparison of the proportion of patients with a status of 2 to 4. NOTE: P < 0.001 for difference in response rate between the two groups (m 2 test). * The chemotherapy regimens included platinum doublet (n = 39), nonplatinum doublet (n = 8), single agent (n = 9), and unknown (n = 5). treatment selection even in male smokers with adenocarcinoma. Studies on North American patients have indicated that those with deletions of exon 19 of EGFR have a better response rate, progression-free survival, and overall survival after EGFR tyrosine kinase inhibitor treatment than do those with the L858R mutation in exon 21 (33, 34) ; however, the present study did not detect a significant difference in progression-free survival or overall survival between the gefitinib-treated patients with exon 19 deletions and those with L858R. Our finding is consistent with previous retrospective analysis of East Asian cohorts showing similar survival benefit of EGFR tyrosine kinase inhibitor treatment in patients with either type of mutation (35, 36) . This apparent difference between North American and East Asian populations might be due to the type of EGFR tyrosine kinase inhibitor (gefitinib or erlotinib) studied, given that all patients in the East Asian cohorts and our present study were treated with gefitinib whereas the North American patients included those treated with erlotinib or gefitinib. Although the biological basis for a possible ethnic difference in EGFR tyrosine kinase inhibitor efficacy according to the type of EGFR mutation remains unknown, it seems that East Asian patients with exon 19 deletions or with L858R benefit equally from gefitinib treatment.
Platinum-based doublet chemotherapy is the standard of care for most patients with advanced non -small cell lung cancer (2, 3) . The substantial clinical benefits of gefitinib treatment in EGFR mutation -positive non -small cell lung cancer patients raise the question about whether first-line gefitinib treatment is more beneficial than systemic chemotherapy in this genotype-defined population. Given that the impact of first-line systemic chemotherapy on EGFR mutation -positive non -small cell lung cancer patients has not been fully evaluated, we compared progression-free survival and overall survival between mutation-positive patients who received first-line gefitinib treatment and those treated initially with systemic chemotherapy. We found that first-line gefitinib treatment yielded a significantly longer progression-free survival than did systemic chemotherapy in EGFR mutation -positive non -small cell lung cancer patients, supporting the use of gefitinib as an initial therapy in this patient population. This finding is consistent with a subset analysis of a recently completed randomized phase III study known as Iressa PanAsia Study, which showed that first-line gefitinib treatment significantly improved the progression-free survival of EGFR mutation -positive patients with advanced non -small cell lung cancer compared with treatment with carboplatin and paclitaxel (37) . We further showed that the significant difference in progression-free survival of EGFR mutation -positive patients according to first-line therapy was not associated with a difference in overall survival likely because all patients treated with systemic chemotherapy as a first-line treatment received gefitinib as a subsequent treatment. This finding suggests that the survival benefit of gefitinib treatment for patients with EGFR mutations is substantial, even when the drug is administered as a second-line therapy, and it raises the question of whether gefitinib is more effective in such patients as a firstline therapy or is equally effective when administered after systemic chemotherapy. Cox regression analysis in the present study revealed that progression-free survival after gefitinib treatment was significantly longer in the chemotherapy-naBve patients than in those who had received previous chemotherapy. Although the impact of systemic chemotherapy on the subsequent efficacy of gefitinib in EGFR mutation -positive patients remains ill defined, our data raise the possibility that systemic chemotherapy may induce biological effects that lead to gefitinib resistance. Elucidation of such effects will be difficult given the challenges associated with repeated tumor biopsy in non-small cell lung cancer patients after the initiation of chemotherapy. Recent randomized phase III studies found that the tolerability profile of gefitinib was better than that of systemic chemotherapy, resulting in improvement in quality of life (9, 10) . Taken together, these data provide support for the treatment of chemotherapy-naBve, EGFR mutation -positive non -small cell lung cancer patients with gefitinib, although well-designed randomized trials that compare EGFR tyrosine kinase inhibitors with standard chemotherapy and monitor quality of life in such patients are warranted.
In conclusion, our combined analysis of updated individual patient data from seven Japanese phase II trials confirmed that gefitinib monotherapy yields substantial clinical benefits in terms of a high response rate and prolonged progression-free survival and overall survival in advanced non -small cell lung cancer patients with EGFR mutations. Our results have important potential implications for clinical practice. The median survival time of f2 years achieved in patients with EGFR mutation -positive non -small cell lung cancer by treatment with gefitinib supports the notion that this group of patients constitutes a clinically distinct population. Furthermore, our exploratory comparison between gefitinib and systemic chemotherapy as a first-line treatment suggests that gefitinib monotherapy is a potentially important first-line treatment option for EGFR mutation -positive non -small cell lung cancer. We are currently doing phase III randomized studies comparing platinum-based chemotherapy with gefitinib in chemotherapy-naBve non -small cell lung cancer patients with EGFR mutations. Such ongoing phase III clinical trials will help determine whether gefitinib monotherapy becomes the standard of care for EGFR mutation -positive non -small cell lung cancer.
